Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Indolent Non-Hodgkin Lymphoma × ibrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42 Lymphoma, Mantle-Cell 20 Waldenstrom Macroglobulinemia 12 Lymphoma, Follicular 10 Lymphoma, Non-Hodgkin 9 Lymphoma, B-Cell 9 Leukemia 9 Lymphoma, Large B-Cell, Diffuse 8 Recurrence 6 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma 5 Neoplasms 3 Leukemia, Lymphoid 3 Leukemia, B-Cell 3 Hodgkin Disease 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 Leukemia, Hairy Cell 2 Chromosome 17 deletion 2 Burkitt Lymphoma 2 Bronchiolitis Obliterans Syndrome 2 Squamous Cell Carcinoma of Head and Neck 1 Smoldering Multiple Myeloma 1 Prostatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Melanoma 1 Mastocytosis, Systemic 1

Interventions

obinutuzumab 1 ibrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689869 2021-05-07

Alternative

Ludwig-Maximilians - University of Munich

Phase 2 Unknown

Indolent Non-Hodgkin Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡